On this page
Brooke-Spiegler syndrome
This rare autosomal dominant disorder typically presents in early adulthood with slow-growing skin growths on the head and neck. Whilst the tumours are benign, they can cause disfigurement and discomfort. Pathogenic variants in CYLD underlie most cases.
Overview
Brooke-Spiegler syndrome is a rare genetic disorder affecting the skin, where individuals develop multiple benign tumours over time. The hallmark growths include cylindromas (often called 'turban tumours' when numerous on the scalp), trichoepitheliomas (tumours of hair follicle origin), and spiradenomas (painful nodules derived from sweat glands). These growths typically emerge during adolescence or early adulthood and increase in number and size throughout life.
The condition follows an autosomal dominant inheritance pattern, meaning a single pathogenic variant in one copy of the responsible gene is sufficient to cause disease. Family history is often positive, though spontaneous cases do occur. Whilst the tumours themselves are benign, they can substantially affect quality of life through cosmetic concerns, discomfort, and in rare instances may undergo malignant transformation. Early recognition and genetic confirmation allow for appropriate surveillance and family planning discussions.
Symptoms & clinical features
The clinical presentation of Brooke-Spiegler syndrome varies considerably between affected individuals, even within the same family. Most people first notice small, skin-coloured or pinkish nodules appearing on the scalp, face, neck, or upper trunk during their teenage years or twenties. Cylindromas often favour the scalp and can become quite large, sometimes coalescing to cover substantial areas. Trichoepitheliomas typically appear on the face, particularly around the nose, forehead, and upper lip as multiple small, firm bumps.
Spiradenomas, when present, tend to be more painful than other tumour types and may cause discomfort even without direct pressure. The number of tumours ranges from a few isolated lesions to hundreds scattered across the head and neck region. Growth is generally slow but progressive, with existing lesions enlarging and new ones appearing over decades. Some individuals experience episodes of more rapid growth or inflammation within tumours. Bleeding, ulceration, or sudden enlargement of a longstanding lesion warrants medical assessment to exclude malignant change, though this remains uncommon.
Video: Genetics 101
Affected organs
Brooke-Spiegler syndrome predominantly affects the skin, with tumours arising from appendageal structures including hair follicles and sweat glands. The scalp and face are most frequently involved, though lesions can develop on the neck, trunk, and occasionally the limbs. The underlying mechanism involves disruption of normal cellular regulation within skin appendages, leading to benign overgrowth.
Whilst the condition is primarily cutaneous, the psychological and social impact should not be underestimated. Extensive facial or scalp involvement can cause significant distress and affect self-image. Large cylindromas on the scalp may become heavy and interfere with hair grooming. There is no systemic involvement affecting internal organs, and general health remains unaffected by the genetic variant itself.
Risks & severity
Severity in Brooke-Spiegler syndrome spans a wide spectrum. Some individuals develop only a handful of small, barely noticeable lesions throughout their lifetime, whilst others experience hundreds of tumours causing substantial disfigurement. There is no reliable way to predict disease severity based on genetic testing alone, and considerable variation occurs even between family members carrying the same pathogenic variant.
The tumours themselves are benign, but rare malignant transformation to cylindrocarcinoma or other skin cancers has been documented in a small minority of cases. This risk appears to increase with age and tumour burden. Large, longstanding cylindromas carry the highest transformation risk. Individuals with extensive disease may require repeated surgical interventions over their lifetime to manage symptomatic or cosmetically troubling lesions. Early-onset disease or rapid tumour growth may indicate more aggressive phenotype, though progression remains generally slow.
Genetic causes
Brooke-Spiegler syndrome results from pathogenic variants in CYLD, located on chromosome 16. This gene encodes CYLD lysine 63 deubiquitinase, an enzyme that cleaves specific ubiquitin linkages from substrate proteins. Through this activity, the protein acts as a negative regulator of several key signalling cascades that govern cell survival and proliferation within skin appendages.
Pathogenic changes in CYLD impair the protein's capacity to restrain NF-κB and JNK pathway activity. When these signalling networks remain inappropriately active, cells within hair follicles and sweat gland structures proliferate beyond normal limits, generating the benign tumours characteristic of the syndrome. Most disease-causing variants produce truncated or absent protein through nonsense changes, frameshift alterations, or gene deletions. Although one functional gene copy remains, this proves inadequate to fully suppress tumour formation over an individual's lifetime, illustrating the gene's role as a tumour suppressor requiring balanced expression.
- CYLD CYLD lysine 63 deubiquitinase
Inheritance pattern
Brooke-Spiegler syndrome follows an autosomal dominant inheritance pattern. This means inheriting a single pathogenic CYLD variant from one parent is sufficient to cause the condition. Each child of an affected parent has a 50 per cent chance of inheriting the familial variant and developing the syndrome.
Males and females are equally likely to inherit and manifest the condition, though some studies suggest women may develop more numerous tumours. Variable expressivity is characteristic, meaning family members with the same variant may experience markedly different severity. Some individuals carrying a pathogenic CYLD variant show minimal or no clinical features, a phenomenon called reduced penetrance. New (de novo) pathogenic variants can occur, so absence of family history does not exclude the diagnosis. Genetic counselling helps families understand recurrence risks and reproductive options including prenatal or preimplantation genetic testing.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of Brooke-Spiegler syndrome typically begins with clinical recognition of characteristic skin tumours, particularly when there is a suggestive family history. A dermatologist may perform skin biopsies of representative lesions to confirm the tumour types histologically. Cylindromas show distinctive 'jigsaw puzzle' arrangements of basaloid cells surrounded by hyaline material. Trichoepitheliomas display features of hair follicle differentiation.
Genetic testing of CYLD provides definitive molecular confirmation. Testing is accessed through NHS clinical genetics services following referral from dermatology or clinical genetics. The condition is included in the NHS Genomic Medicine Service PanelApp under skin disorders. Identification of a pathogenic CYLD variant confirms the diagnosis, guides surveillance planning, and enables predictive testing for at-risk family members. However, failure to identify a variant does not exclude the diagnosis, as some individuals may harbour variants in non-coding regions or other genes not routinely tested.
Management & lifestyle
Management of Brooke-Spiegler syndrome focuses on surveillance, surgical intervention for symptomatic lesions, and psychosocial support. Regular dermatology review allows monitoring of tumour progression and early detection of any concerning changes suggesting malignant transformation. Patients are typically advised to report rapidly enlarging lesions, ulceration, or persistent pain promptly.
Surgical excision remains the mainstay of treatment for problematic tumours causing discomfort, bleeding, or cosmetic distress. Options include conventional excision, laser ablation, electrodessication, or cryotherapy depending on lesion characteristics and patient preference. Large cylindromas may require complex reconstruction. Because new tumours continue appearing throughout life, repeat procedures are often necessary. Some individuals opt for regular 'debulking' surgeries to manage tumour burden. Aspirin and other salicylates have shown promise in laboratory studies for their potential to modulate signalling pathways affected by CYLD loss, though robust clinical trial evidence for chemoprevention remains limited. Sun protection is generally recommended, as with any condition affecting skin integrity. Psychological support and access to specialist dermatology nursing can substantially improve quality of life for those with extensive disease.
UK care pathway
Within the NHS, suspected Brooke-Spiegler syndrome typically prompts dermatology referral initially. Following clinical assessment and biopsy confirmation of characteristic tumour types, onward referral to clinical genetics services enables genetic testing and family counselling. The condition falls within the Genomic Medicine Service skin disorder testing criteria. Genetic testing through the NHS identifies causative CYLD variants and confirms the diagnosis molecularly.
Once diagnosed, ongoing care involves shared management between dermatology and clinical genetics. Dermatology provides surveillance and surgical intervention as needed, whilst genetic counselling supports families in understanding inheritance, family screening, and reproductive options. Some patients may benefit from involvement of plastic surgery services for complex reconstructive procedures. Genetic counsellors can facilitate predictive testing for at-risk relatives and provide guidance on family planning considerations.
Frequently asked questions
Will my children definitely develop Brooke-Spiegler syndrome if I have it?
Each of your children has a 50 per cent chance of inheriting the pathogenic CYLD variant. However, inheriting the variant does not guarantee they will develop tumours, and if they do, the severity may differ substantially from your own experience due to variable expressivity.
Can the tumours in Brooke-Spiegler syndrome become cancerous?
Whilst the tumours are benign in the vast majority of cases, malignant transformation occurs rarely, typically in longstanding or large cylindromas. Regular monitoring helps detect any concerning changes early, such as rapid growth or ulceration.
Is there any way to prevent new tumours from forming?
Currently, there is no proven medical therapy to prevent tumour development entirely. Research into medications that might slow tumour growth continues, but evidence remains preliminary. Surgical removal addresses existing tumours but does not prevent new ones appearing.
How often should I be seen by a dermatologist?
Surveillance frequency depends on your individual tumour burden and rate of progression. Many adults with established disease benefit from annual or six-monthly dermatology review, though your specialist will tailor the schedule to your circumstances and can advise on self-monitoring between appointments.
Does Brooke-Spiegler syndrome affect anything other than the skin?
The condition affects only the skin and does not involve internal organs. General health remains unaffected by the genetic variant itself, though the psychological impact of visible tumours can be significant for some individuals.
References
- Correia C, Soares-de-Almeida L. Brooke-Spiegler syndrome. Medicina clinica. 2023. PMID: 36997442
- Neema S, Sandhu S, Radhakrishnan S. Brooke-Spiegler syndrome. Indian journal of dermatology, venereology and leprology. 2023. PMID: 33666057
- Mohiuddin W, Laun J, Cruse W. Brooke-Spiegler Syndrome. Eplasty. 2018. PMID: 30093932
- Kazakov DV. Brooke-Spiegler Syndrome and Phenotypic Variants: An Update. Head and neck pathology. 2016. PMID: 26971504
- Brambullo T, De Lazzari A, Franchi A. A Misdiagnosed Familiar Brooke-Spiegler Syndrome: Case Report and Review of the Literature. Journal of clinical medicine. 2024. PMID: 38673513
- Szepietowski JC, Wasik F, Szybejko-Machaj G. Brooke-Spiegler syndrome. Journal of the European Academy of Dermatology and Venereology : JEADV. 2001. PMID: 11730050
- Adam MP, Bick S, Mirzaa GM. CYLD Cutaneous Syndrome. 1993. PMID: 32298062
- Myers DJ, Sathe NC, Fillman EP. Cylindroma. 2024. PMID: 29489215